Seat­tle’s Im­pel Neu­roPhar­ma bags $67.5M crossover raise for a round of new drug/de­vice CNS clin­i­cal tri­als

A Seat­tle-based drug/de­vice com­pa­ny with its own par­tic­u­lar ap­proach for get­ting drugs de­liv­ered in­to the brain through the nose has put to­geth­er a top-notch syn­di­cate that’s de­liv­ered $67.5 mil­lion in Se­ries D cash.

KKR and Nor­west Ven­ture Part­ners led the round for Im­pel, with Vi­vo Cap­i­tal, 5AM Ven­tures and ven­Bio Part­ners jump­ing in. Ali Sat­vat, who heads up KKR’s new $1.5 bil­lion health­care fund, is jump­ing on the board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER